Gabe Kwong

Associate Professor
Director, Laboratory for Synthetic Immunity

Dr. Gabe Kwong is an Assistant Professor in the Wallace H. Coulter Department of Biomedical Engineering at the Georgia Tech School of Engineering and Emory School of Medicine. His research program is conducted at the interface of the life sciences, medicine and engineering where a central focus is understanding how to harness the sophisticated defense mechanisms of immune cells to eradicate disease and provide protective immunity. Kwong has pioneered numerous biomedical technologies and published in leading scientific journals such as Nature Biotechnology and Nature Medicine. His work has been profiled broadly including coverage in The Economist, NPR, BBC, and WGBH-2, Boston 's PBS station. Professor Kwong earned his B.S. in Bioengineering with Highest Honors from the University of California, Berkeley and his Ph.D. in Bioengineering from California Institute of Technology with Professor James R. Heath. He conducted postdoctoral studies at Massachusetts Institute of Technology with Professor Sangeeta N. Bhatia. For his work, Dr. Kwong has been awarded the NIH Ruth L. Kirschstein National Research Service Award, named a "Future Leader in Cancer Research and Translational Medicine" by the Massachusetts General Hospital, and awarded the Burroughs Wellcome Fund Career Award at the Scientific Interface, a distinction given to the 10 most innovative bioengineers in the nation. Dr. Kwong holds seven issued or pending patents in cancer nanotechnology.

gkwong@gatech.edu

404-385-3746

Office Location:
Marcus Nanotechnology 3132

Website

  • Related Site

    • Google Scholar


    Georgia Institute of Technology

    Wallace H. Coulter Department of Biomedical Engineering
    Research Focus Areas:
  • Biomaterials
  • Cancer Biology
  • Cell Manufacturing
  • Chemical Biology
  • Drug Design, Development and Delivery
  • Miniaturization & Integration
  • Nanomaterials
  • Systems Biology
    • Additional Research:
    Human health has been transformed by our collective capacity to engineer immunity — from the pivotal development of the smallpox vaccine to the curative potential of recent cancer immunotherapies. These examples motivate our research program that is conducted at the interface of Engineering and Immunology, and where we develop biomedical technologies and applications that shape a diverse array of immunological systems.

    The questions that are central to our exploration include: How do we begin to study an individual's repertoire of well over one billion immune cells when current technologies only allow us to study a handful of cells at a time? What are the biomarkers of immunological health as the body responds to disease and ageing, and how may these indicators trigger clinical decisions? And how can we genetically rewire immune cells to provide them with entirely new functions to better fight complex diseases such as cancer?

    To aid in our studies, we use high-throughput technologies such as next-generation sequencing and quantitative mass spectrometry, and pioneer the development of micro- and nanotechnologies in order to achieve our goals. We focus on clinical problems in cancer, infectious diseases and autoimmunity, and ultimately strive to translate key findings into therapies for patients.
    Linkedin

    Research Affiliations: Integrated Cancer Research Center, Immunoengineering, Center for ImmunoEngineering

    IRI Connection: